Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
13 Diciembre 2023 - 6:00AM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing a new class of small molecule
medicines using targeted protein degradation (TPD), today shared
webcast information for the virtual Immunology R&D Day that the
Company will host on January 4, 2024, from 10:00 a.m. to 12:00 p.m.
ET. The R&D Day will focus on the Company’s emerging pipeline
of high-value immunology programs, including new target
disclosures, supporting preclinical data and timing to clinical
study initiation.
To join the webcast, please visit this link, or the “Events and
Presentations” page of the Investors section on the Company’s
website at www.kymeratx.com. A replay of the webcast will be
archived and available following the event.
About Kymera Therapeutics
Kymera is a biopharmaceutical company pioneering the field of
targeted protein degradation, a transformative approach to address
disease targets and pathways inaccessible with conventional
therapeutics. Kymera’s Pegasus platform is a powerful drug
discovery engine, advancing novel small molecule programs designed
to harness the body’s innate protein recycling machinery to degrade
dysregulated, disease-causing proteins. With a focus on undrugged
nodes in validated pathways, Kymera is advancing a pipeline of
novel therapeutic candidates designed to address the most promising
targets and provide patients with more effective treatments.
Kymera’s initial programs target IRAK4 and STAT3 within the
IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein, providing
the opportunity to treat patients with a broad range of
immune-inflammatory diseases, hematologic malignancies, and solid
tumors.
Founded in 2016, Kymera is headquartered in Watertown, Mass.
Kymera has been named a “Fierce 15” company by Fierce Biotech and
has been recognized by both the Boston Globe and the Boston
Business Journal as one of Boston’s top workplaces. For more
information about our people, science, and pipeline, please visit
www.kymeratx.com or follow us on X (formerly Twitter) or
LinkedIn.
Investor Contact: |
Media Contact: |
|
|
Justine Koenigsberg |
Todd Cooper |
Vice President, Investor
Relations |
Senior Vice President, Corporate
Affairs |
investors@kymeratx.com |
media@kymeratx.com |
857-285-5300 |
857-285-5300 |
Kymera Therapeutics (NASDAQ:KYMR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Kymera Therapeutics (NASDAQ:KYMR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024